Brazilian Journal of Psychiatry · 2006 · 20 citations · 7 references
MedicinePharmacologyPsychiatryAdult PsychiatryDementiaPsychopharmacologyAntipsychotic PharmacotherapyAntipsychotic TherapyMetabolic SyndromePsychiatric EpidemiologyPsychotic DisordersSchizophrenia Spectrum DisordersAnthropometric SamplingAntipsychotic Medication UseAntipsychotic Use In DementiaCross-sectional EpidemiologyLow Body Mass IndexPsychotic Disorders DiagnosisSchizophrenia Spectrum Symptom Assessment
OBJECTIVE: First and second generation antipsychotics are associated with metabolic disturbances. A cross-sectional study was designed to follow outpatients at the Schizophrenia and Dementia Program at a major teaching hospital in Porto Alegre, Brazil (Hospital de Clínicas de Porto Alegre) in order to verify whether second generation antipsychotics were associated with higher glucose and lipid levels regardless of age and gender. METHOD: Four metabolic parameters (cholesterol and fractions, glucose and triglycerides) and anthropometric measures were obtained from 124 consecutive adult outpatients diagnosed with schizophrenia by DSM-IV and ICD-10 with the Operational Criteria Checklist for Psychotic Disorders system using the same antipsychotic drug for at least 9 weeks. RESULTS: Most patients had elevated BMI (76.6%) and dyslipidemia (84.7%). Clozapine users had lower HDL levels compared to first generation antipsychotics users. Both groups had elevated body mass index (p = 0.033; OR = 3.3; 95%CI = 1.1-9.8) and second generation antipsychotics (p = 0.021; OR = 3.5; 95%CI = 1.1-11.2) showed significant effect, adjusted for age and gender in the logistic regression for dyslipidemia, and significant age effect for hyperglycemia (p = 0.030; OR = 1.1; 95%CI = 1.0-1.1). DISCUSSION: There was statistically significant association between the use of second generation antipsychotics and dyslipidemia. It raises the issue of increased vulnerability of second generation antipsychotics-treated patients, regardless of age, as well as the need for assertive treatment for overweight and dyslipidemia in schizophrenia in order to reduce the risk of diabetes and cardiovascular disease.
7
Evaluation Expert Panel on Detection · JAMA · 2001 · 26K citations
Medicine, Cardiology, Otolaryngology +10
Diabetes mellitus in schizophrenic patients
Sukdeb Mukherjee, Paolo Decina, Vittorio Bocola et al. · Comprehensive Psychiatry · 1996 · 371 citations
Medicine, Endocrinology, Psychiatry +11
Paul Mackin, Helen Watkinson, Andrew Young · Diabetologia · 2005 · 116 citations · Full text
Medicine, Endocrinology, Psychiatry +16